


## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4093946

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	CHANGE OF NAME	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	AVI BIOPHARMA, INC.	07/10/2012
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	SAREPTA THERAPEUTICS, INC.	
<b>Street Address:</b>	4575 S.W. RESEARCH WAY	
<b>Internal Address:</b>	SUITE 200	
<b>City:</b>	CORVALLIS	
<b>State/Country:</b>	OREGON	
<b>Postal Code:</b>	97333	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	14977451
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(857)300-4001	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	857-300-4003	
<b>Email:</b>	bostonpatent@lathropgage.com,dvincent@lathropgage.com	
<b>Correspondent Name:</b>	LATHROP & GAGE LLP, BRIAN C. TRINQUE, PH.D., ESQ.	
<b>Address Line 1:</b>	28 STATE STREET	
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02109	
<b>ATTORNEY DOCKET NUMBER:</b>	582998: SPT-8076CON	
<b>NAME OF SUBMITTER:</b>	BRIAN C. TRINQUE, PH.D., ESQ.	
<b>SIGNATURE:</b>	/BRIAN C. TRINQUE/	
<b>DATE SIGNED:</b>	10/12/2016	
<b>Total Attachments: 5</b>		
source=582998_SPT-8076CON4_EXECUTED_CONFIRMATORY_ASSIGNMENT 10-12-16#page1.tif		
source=582998_SPT-8076CON4_EXECUTED_CONFIRMATORY_ASSIGNMENT 10-12-16#page2.tif		
source=582998_SPT-8076CON4_EXECUTED_CONFIRMATORY_ASSIGNMENT 10-12-16#page3.tif		
source=582998_SPT-8076CON4_EXECUTED_CONFIRMATORY_ASSIGNMENT 10-12-16#page4.tif		
source=582998_SPT-8076CON4_EXECUTED_CONFIRMATORY_ASSIGNMENT 10-12-16#page5.tif		



Secretary of State  
Corporation Division  
255 Capitol Street NE, Suite 151  
Salem, OR 97310-1327

Phone: (503) 986-2200  
www.filinginoregon.com

Registry Number: 145980-15  
Type: DOMESTIC BUSINESS CORPORATION

Next Renewal Date: 07/22/2012

SAREPTA THERAPEUTICS, INC.  
3450 MONTE VILLA PARKWAY STE 101  
BOTHELL WA 98021

### Acknowledgment Letter

The document you submitted was recorded as shown below. Please review and verify the information listed for accuracy.

**Document**  
ARTICLES OF AMENDMENT

**Filed On**  
07/11/2012

**Jurisdiction**  
OREGON

**Name**  
SAREPTA THERAPEUTICS, INC.

**Principal Place of Business**  
3450 MONTE VILLA PARKWAY STE 101  
BOTHELL WA 98021

**Registered Agent**  
NATIONAL REGISTERED AGENTS, INC.  
325 13TH ST NE STE 501  
SALEM OR 97301

**Mailing Address**  
3450 MONTE VILLA PARKWAY STE 101  
BOTHELL WA 98021

**President**  
CHRISTOPHER GARABEDIAN  
3450 MONTE VILLA PARKWAY STE 101  
BOTHELL WA 98021

**Secretary**  
EFFIE TOSHAV  
3450 MONTE VILLA PARKWAY STE 101  
BOTHELL WA 98021

HEAPRE  
ACK  
07/11/2012

**PATENT**  
**REEL: 040332 FRAME: 0943**

**Articles of Amendment - Business/Professional**Secretary of State - Corporation Division - 255 Capitol St. NE, Suite 151 - Salem, OR 97310-1327 - <http://www.FilingInOregon.com> - Phone: (503) 986-2200**FILED****JUL 11 2012****OREGON  
SECRETARY OF STATE**REGISTRY NUMBER: 145980-15

In accordance with Oregon Revised Statute 192.410-192.490, the information on this application is public record. We must release this information to all parties upon request and it will be posted on our website.

For office use only

Please Type or Print Legibly in Black Ink.

1) ENTITY NAME: AVI BIOPHARMA, INC.

2) STATE THE ARTICLE NUMBER(s): and set forth the article(s) as it is amended to read. (Attach a separate sheet if necessary.)

Articles I and II as set forth on Exhibit A attached hereto.3) THE AMENDMENT WAS ADOPTED ON: July 10, 2012

(If more than one amendment was adopted, identify the date of adoption of each amendment.)

4) CHECK THE APPROPRIATE STATEMENT:

☒ Shareholder action was required to adopt the amendment(s).

The vote was as follows:

Class or series of shares	Number of shares outstanding	Number of votes entitled to be cast	Number of votes cast FOR	Number of votes cast AGAINST
See Attached Vote				

☐ Shareholder action was not required to adopt the amendment(s). The amendment(s) was adopted by the board of directors without shareholder action.☐ The corporation has not issued any shares of stock. Shareholder action was not required to adopt the amendment(s). The amendment(s) was adopted by the incorporators or by the board of directors.

5) EXECUTION: (Must be signed by at least one officer or director.)

By my signature, I declare as an authorized authority, that this filing has been examined by me and is, to the best of my knowledge and belief, true, correct, and complete. Making false statements in this document is against the law and may be penalized by fines, imprisonment or both.

Signature: 

Printed Name:

Christopher Garabedian

Title:

President and CEO

CONTACT NAME: (To resolve questions with this filing.)

Linda J. Lorenat

PHONE NUMBER: (Include area code.)

(650) 463-2656

FEES  
Required Processing Fee \$100  
No Fee for President/Secretary Change.  
Processing Fees are nonrefundable. Please make check payable to "Corporation Division."  
Free copies are available at [www.FilingInOregon.com](http://www.FilingInOregon.com) using the Business Name Search program.

**ATTACHMENT**  
**to**  
**ARTICLES OF AMENDMENT**

The amendment of the Fourth Restated and Amended Articles of Incorporation required shareholder approval. The record date for such shareholder approval was set as May 14, 2012 (the "Record Date"). The vote of shareholders as of the Record Date was as follows:

Shareholder approval to amend the Fourth Restated and Amended Articles of Incorporation to change the name of the Company from "AVI BioPharma, Inc." to "Sarepta Therapeutics, Inc.":

<b>Designation of Security</b>	<b>Number of Outstanding Shares</b>	<b>Number of Votes Entitled to be Cast</b>	<b>Number of Votes Cast FOR</b>	<b>Number of Votes Cast AGAINST</b>
Common Stock	135,743,787	135,743,787	104,286,234	12,268,753

Shareholder approval to amend the Fourth Restated and Amended Articles of Incorporation to effect a 1-for-6 reverse stock split:

<b>Designation of Security</b>	<b>Number of Outstanding Shares</b>	<b>Number of Votes Entitled to be Cast</b>	<b>Number of Votes Cast FOR</b>	<b>Number of Votes Cast AGAINST</b>
Common Stock	135,743,787	135,743,787	93,284,765	23,270,222

**EXHIBIT A**

**AMENDMENT TO FOURTH RESTATED AND AMENDED  
ARTICLES OF INCORPORATION  
OF  
AVI BIOPHARMA, INC.**

1. **Amendment to Article I.** Article I is hereby amended in its entirety to read as follows:

**“ARTICLE I.  
Name**

The name of the Corporation is Sarepta Therapeutics, Inc.”

2. **Amendment to Article II.** Section 2.1 of Article II is hereby amended in its entirety to read as follows:

“2.1 *Authorized Capital.* The Corporation is authorized to issue two classes of stock which are designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares of stock which the Corporation shall have authority to issue shall be 53,333,333, consisting of 50,000,000 shares of Common Stock, having \$0.0001 par value per share, and 3,333,333 shares of Preferred Stock, having \$0.0001 par value per share.”

Article II is hereby amended to insert the following Section 2.1A immediately following Section 2.1:

“2.1A *Reverse Stock Split.* Effective upon the filing date of these Articles of Amendment (the “Effective Time”), the Corporation shall effect a reverse split in its issued and outstanding shares of Common Stock so that the shares currently issued and outstanding shall be reverse split, or consolidated, on a 1-for-6 basis, and shareholders shall receive one share of the Corporation’s post-split Common Stock for each six shares of Common Stock held by them prior to the reverse split (the “Reverse Stock Split”). In lieu of any fractional share to which a holder would otherwise be entitled, after aggregating all such fractions of a share, such holder shall be entitled to receive cash in an amount equal to the product obtained by multiplying such fraction by the average closing price of the Corporation’s Common Stock as quoted on the Nasdaq Global Market for the five trading days immediately preceding the filing date of these Articles of Amendment, such payment to be made by the Corporation upon surrender of a certificate or certificates representing the shares of Common Stock of the Corporation issued and outstanding immediately prior to the Effective Time held by such holder, together with a properly completed and executed transmittal form, which shall be provided to all shareholders of record, to the Corporation’s transfer agent acting on the Corporation’s behalf. The Corporation’s transfer agent, acting on the Corporation’s behalf, shall provide certificates representing the split, consolidated and reclassified shares of Common Stock of the Corporation in exchange for and upon receipt and surrender of certificates representing shares of the Common Stock of the

Corporation issued and outstanding immediately prior to the Effective Time. From and after the Effective Time, certificates representing shares of Common Stock of the Corporation issued and outstanding immediately prior to the Effective Time until they are surrendered shall represent only the right of the holders thereof to receive shares of the split, consolidated and reclassified shares of Common Stock of the Corporation resulting from the Reverse Stock Split.

\* \* \*

Except as amended above in this Amendment, the Fourth Restated and Amended Articles of Incorporation shall remain in full force and effect.

SV916427.1